These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22782280)

  • 1. Just because it's low cost doesn't mean it's accessible.
    Qato DM; Alexander GC
    J Gen Intern Med; 2012 Oct; 27(10):1233-4. PubMed ID: 22782280
    [No Abstract]   [Full Text] [Related]  

  • 2. Prescriptions by mail improve access and affordability to medications for Medicare Part D beneficiaries.
    Frazee SG; Henderson R; Iyengar R
    J Manag Care Spec Pharm; 2014 Oct; 20(10):991. PubMed ID: 25278320
    [No Abstract]   [Full Text] [Related]  

  • 3. It's time to bail out seniors trapped in the Medicare donut hole!
    Dalen JE
    Am J Med; 2009 Jul; 122(7):595-6. PubMed ID: 19559156
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the effects of Medicare Part D from key stakeholders' perspectives: Important progress, but abundant research opportunities remain.
    Urmie JM; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):85-9. PubMed ID: 20511107
    [No Abstract]   [Full Text] [Related]  

  • 6. Medicare Part D update--lessons learned and unfinished business.
    Neuman P; Cubanski J
    N Engl J Med; 2009 Jul; 361(4):406-14. PubMed ID: 19625722
    [No Abstract]   [Full Text] [Related]  

  • 7. Prescription drug coverage among elderly and disabled Americans: can Medicare-Part D reduce inequities in access?
    Kanavos P; Gemmill-Toyama M
    Int J Health Care Finance Econ; 2010 Sep; 10(3):203-18. PubMed ID: 20213234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDPs see increases in cost-sharing amounts.
    Manag Care; 2009 Aug; 18(8):55. PubMed ID: 19731513
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more?
    Mott DA; Thorpe JM; Thorpe CT; Kreling DH; Gadkari AS
    Res Social Adm Pharm; 2010 Jun; 6(2):90-9. PubMed ID: 20511108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare Part D: Patients Bear The Cost Of 'Me Too' Brand-Name Drugs.
    Gastala NM; Wingrove P; Gaglioti A; Petterson S; Bazemore A
    Health Aff (Millwood); 2016 Jul; 35(7):1237-40. PubMed ID: 27385239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How do seniors respond to 100% cost-sharing for prescription drugs? Quality of the evidence underlying opinions about the Medicare Part D coverage gap.
    Fairman KA; Curtiss FR
    J Manag Care Pharm; 2011 Jun; 17(5):382-92. PubMed ID: 21657807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimizing out-of-pocket prescription drug costs for Medicare beneficiaries: not just 'a drop in the bucket'.
    Patel RA; Vo KA; Chu T; Wang K; Lu S; Woelfel JA; Carr-Lopez SM; Galal SM
    J Am Pharm Assoc (2003); 2014; 54(6):604-9. PubMed ID: 25379981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Top 40 Medicare Part D prescription drugs Ranked by total payments in 2014.
    Mod Healthc; 2016 Oct; 46(36):42. PubMed ID: 30398720
    [No Abstract]   [Full Text] [Related]  

  • 15. Recommendations for Lowering Prescription Drug Spending in Public Programs.
    Jazowski SA; Dusetzina SB
    Ann Intern Med; 2019 Dec; 171(11):855-856. PubMed ID: 31711129
    [No Abstract]   [Full Text] [Related]  

  • 16. Providing prescription drug coverage to the elderly: America's experiment with Medicare Part D.
    Duggan M; Healy P; Morton FS
    J Econ Perspect; 2008; 22(4):69-92. PubMed ID: 19768843
    [No Abstract]   [Full Text] [Related]  

  • 17. Favorable Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available.
    Socal MP; Bai G; Anderson GF
    JAMA Intern Med; 2019 Jun; 179(6):832-833. PubMed ID: 30882842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors.
    Egilman AC; Zhang AD; Wallach JD; Ross JS
    Ann Intern Med; 2019 Oct; 171(7):521-523. PubMed ID: 31404926
    [No Abstract]   [Full Text] [Related]  

  • 19. Changing Medicare's Protected Classes: History, Mistrust, and Budgets in the Prescription Drug Market.
    Frank RG
    Psychiatr Serv; 2019 Oct; 70(10):858-859. PubMed ID: 31480929
    [No Abstract]   [Full Text] [Related]  

  • 20. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
    Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
    JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.